Head and Neck Neoplasm - Squamous Cell Carcinoma
NCT00956007
Clinical Trial Information
Trial Number: NCT00956007 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer"
Study ID:
RTOG-0920
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
NCT03258554
Clinical Trial Information
Trial Number: NCT03258554 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
"Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin"
Study ID:
NRG-HN004
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT03258554-D4 | This data submission (NCT03258554-D4) contains the baseline, treatment, and adverse event data used to generate the results for the lead-in phase analysis in PubMed ID = 39551064, a publication analyzing the primary endpoint of NRG-HN004. NCT03258554-D1 contains baseline, treatment, and outcome data for the phase II extended follow-up analysis. NCT03258554-D2 contains all adverse events for the phase II extended follow-up analysis. NCT03258554-D3 contains outcome data for the phase II prespecified analysis. |
| NCT03258554-D3 | This data submission (NCT03258554-D3) contains the outcome data used to generate the results for the phase II prespecified analysis in PubMed ID = 39551064, a publication analyzing the primary endpoint of NRG-HN004. NCT03258554-D1 contains baseline, treatment, and outcome data for the phase II extended follow-up analysis. NCT03258554-D2 contains all adverse events for the phase II extended follow-up analysis. NCT03258554-D4 contains data for the lead-in phase. |
| NCT03258554-D2 | This data submission (NCT03258554-D2) contains the adverse event data used to generate the results for the phase II extended follow-up analysis in PubMed ID = 39551064, a publication analyzing the primary endpoint of NRG-HN004. NCT03258554-D1 contains baseline, treatment, and outcome data for the phase II extended follow-up analysis. NCT03258554-D3 contains outcome data for the phase II prespecified analysis. NCT03258554-D4 contains data for the lead-in phase. |
| NCT03258554-D1 | This data submission (NCT03258554-D1) contains baseline, treatment, and outcome data used to generate the results for the phase II extended follow-up analysis in PubMed ID = 39551064, a publication analyzing the primary endpoint of NRG-HN004. NCT03258554-D2 contains all adverse events for the phase II extended follow-up analysis. NCT03258554-D3 contains outcome data for the phase II prespecified analysis. NCT03258554-D4 contains data for the lead-in phase. |
NCT00588770
Clinical Trial Information
Trial Number: NCT00588770 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Study ID:
E1305
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
NCT02254278
Clinical Trial Information
Trial Number: NCT02254278 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Study ID:
NRG-HN002
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
NCT00939627
Clinical Trial Information
Trial Number: NCT00939627 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients with Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study ID:
8070
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00939627-D1 | There are two different submissions (each with one dataset) for PMID 30926065 from trial E5397 and 8070. This dataset, NCT00939627-D1 contains data for 8070. Dataset NCT00003809-D1 contains data for trial E5397. |
NCT00003809
Clinical Trial Information
Trial Number: NCT00003809 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients with Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck
Study ID:
E5397
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00003809-D1 | There are two different submissions (each with one dataset) for PMID 30926065 from trial E5397 and 8070. This dataset, NCT00003809-D1, contains data for trial E5397. Dataset NCT00939627-D1 contains data for 8070. |
NCT01302834
Clinical Trial Information
Trial Number: NCT01302834 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
Study ID:
RTOG-1016
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT01302834-D2 | This dataset will allow users to reproduce the treatment comparison between arm 1 and arm 2 in trial NCT01302834. Specifically, this dataset contains the highest treatment-related adverse event grade per CTCAE term per time period (acute/late). |
| NCT01302834-D1 | This dataset will allow users to reproduce the treatment comparison between arm 1 and arm 2 in trial NCT01302834. Specifically, this dataset contains baseline, treatment, survival, pre-specified treatment related adverse event, swallowing domain, and dental gingival health data. |
NCT00265941
Clinical Trial Information
Trial Number: NCT00265941 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas
Study ID:
RTOG-0522
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00265941-D2 | This dataset will allow users to reproduce the adverse event tables in trial NCT00265941. |
| NCT00265941-D1 | This dataset will allow users to reproduce the treatment comparison between arms in trial NCT00265941. |
NCT03370367
Clinical Trial Information
Trial Number: NCT03370367 (ClinicalTrials.gov)
Disease Type:
- Head and Neck Neoplasm - Squamous Cell Carcinoma
Trial Title:
Double-blind Phase III trial of effects of low-dose 13-cis retinoic acid on prevention of second primaries in stages i-ii head and neck cancer
Study ID:
C0590
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT03370367-D1 | This dataset contains baseline, efficacy, 13-CRA toxicity, and CTC toxicity data from trial NCT03370367. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®